ReviewJournal of immunology research2014
Respiratory syncytial virus infections in infants affected by primary immunodeficiency.
Review in Journal of immunology research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Article
- Hospital admissions and need for mechanical ventilation in children with respiratory syncytial virus before and during the COVID-19 pandemic: a Danish nationwide cohort study.The Lancet. Child & adolescent health · 2023Article
- Metal Nanoparticles: a Promising Treatment for Viral and Arboviral Infections.Biological trace element research · 2021Review
- Inborn Errors of Immunity in the Premature Infant: Challenges in Recognition and Diagnosis.Frontiers in immunology · 2021Review
- Respiratory Syncityal Virus A and B: three bronchiolitis seasons in a third level hospital in Italy.Italian journal of pediatrics · 2019Article
- Sex-associated TSLP-induced immune alterations following early-life RSV infection leads to enhanced allergic disease.Mucosal immunology · 2019Article
- Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study.BMC infectious diseases · 2018Observational
- RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations.Expert review of clinical immunology · 2017Review
- Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection.International journal of molecular sciences · 2017Review
- Burden of Respiratory Syncytial Virus Hospitalizations in Canada.Canadian respiratory journal · 2017Article
- Recurrent and Sustained Viral Infections in Primary Immunodeficiencies.Frontiers in immunology · 2017Review
- Primary Immunodeficiency Diseases in Oman: 10-Year Experience in a Tertiary Care Hospital.Journal of clinical immunology · 2016Article
- The European Hematology Association Roadmap for European Hematology Research: a consensus document.Haematologica · 2016Article
- Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus.Bone marrow transplantation · 2016Article
- Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV).Italian journal of pediatrics · 2015Review
- Therapeutic Immunoglobulin Selected for High Antibody Titer to RSV also Contains High Antibody Titers to Other Respiratory Viruses.Frontiers in immunology · 2015Article
- Immunological, Viral, Environmental, and Individual Factors Modulating Lung Immune Response to Respiratory Syncytial Virus.BioMed research international · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary immunodeficiencies are rare inherited disorders that may lead to frequent and often severe acute respiratory infections. Respiratory syncytial virus (RSV) is one of the most frequent pathogens during early infancy and the infection is more severe in immunocompromised infants than in healthy infants, as a result of impaired T- and B-cell immune response unable to efficaciously neutralize viral replication, with subsequent increased viral shedding and potentially lethal lower respiratory tract infection. Several authors have reported a severe clinical course after RSV infections in infants and children with primary and acquired immunodeficiencies. Environmental prophylaxis is essential in order to reduce the infection during the epidemic season in hospitalized immunocompromised infants. Prophylaxis with palivizumab, a humanized monoclonal antibody against the RSV F protein, is currently recommended in high-risk infants born prematurely, with chronic lung disease or congenital heart disease. Currently however the prophylaxis is not routinely recommended in infants with primary immunodeficiency, although some authors propose the extension of prophylaxis to this high risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.